• Disciplinary proceedings opened against Croatian Football Federation
  
• Fowl Ball” Could Be A Huge Hit For Young Sluggers
  
• New Chief Executive of the Meat Hygiene Service appointed
  
• Sale of British Airways Travel Clinic
  
• Lufthansa resumes flights to Beirut
  
• Partnership for Change with Air Navigation Service Providers, Cost Efficiency, Environment
  
• Head-to-head study comparing Lexiva® to Kaletra presented at IAC 2006 and published in The Lancet
  
• Eli Lilly and Company Announces Approvable Letter Issued by FDA for Arxxant TM
  
• Medicines, money and motivated health workers are key...
  
• Skindividual preserve skin’s youthful beauty
  
• A weekend in Paris
  
• Fifth Annual EA Sports Madden Challenge Starts September 1st to...
  
• Akamai and Instant Media Team to Deliver Seamless High-Definition Internet Video Experience
  
• Teva Announces Launch of Generic Zoloft®
  
• Zoller Wine Styling Offers Custom Made Premium Winemaking
  

Teva Comments on Pfizer Press Release Regarding Azithromycin

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today commented on Pfizer s February 8th press release regarding azithromycin.

Although Teva has not yet seen the Citizen Petition or the complaint relating to the infringement actions referenced in the press release, Teva believes that these allegations are baseless and without merit. Furthermore, the Company believes that Pfizer s efforts here are a thinly veiled attempt to discredit Teva and the entire generic drug industry, which have been providing affordable, safe pharmaceutical products to patients for decades.

Teva s azithromycin is a self developed product and is protected by U.S. Patent No. 6,365,574 issued and assigned to Teva on April 2, 2002. Teva s proprietary process for the manufacture of azithromycin monohydrate predates Pfizer s U.S. Patent No. 6,977,243 ( the sesquihydrate patent ) regarding the sesquihydrate form of the product. Teva has substantial defenses to Pfizer s enforcement of the sesquihydrate patent.

Teva s azithromycin active pharmaceutical ingredient is manufactured by its own API division. The final product contains azithromycin monohydrate as stated on the label and as approved by the FDA.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Close to 90% of Teva s sales are in North America and Europe.

Teva Pharmaceutical Industries Ltd.

• Teva Announces Launch of Generic Zoloft®
  
• Teva Provides Generic Biaxin® Xl Update
  
• Teva Announces Tentative Approval for Generic Cozaar® Tablets
  
• Teva Provides Update on Generic Pravachol Exclusivity
  
• Teva Comments on Pfizer Press Release Regarding Azithromycin
  
• Teva Announces Approval of Cefprozil Tablets and Cefprozil for Oral Suspension Usp
  
• Teva and Ivax Receive European Commission Approval for Acquisition
  
• Teva and Barr Announce Launch of Generic Allegra® Tablets by Teva Under Agreement With Barr
  
• Court Grants Teva Summary Judgment of Non-Infringement on Gabapentin
  
• Teva Announces Tentative Approval of Granisetron Hydrochloride Injection